Holen Sie sich die Stockscreener-App
121.05
1.04%
1.25
Handel nachbörslich:
121.04
-0.010
-0.01%
Schlusskurs vom Vortag:
$119.80
Offen:
$119.98
24-Stunden-Volumen:
466.85K
Relative Volume:
0.56
Marktkapitalisierung:
$10.07B
Einnahmen:
$51.48M
Nettoeinkommen (Verlust:
$-315.00M
KGV:
-33.90
EPS:
-3.5708
Netto-Cashflow:
$-244.00M
1W Leistung:
-0.30%
1M Leistung:
+9.48%
6M Leistung:
+33.01%
1J Leistung:
+174.49%
1-Tages-Spanne:
$116.46
$121.56
1-Wochen-Bereich:
$116.46
$127.36
52-Wochen-Spanne:
$39.84
$130.05
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Firmenname
Kymera Therapeutics Inc
Sektor
Branche
Telefon
857-285-5314
Adresse
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Compare KYMR vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KYMR
Kymera Therapeutics Inc
|
121.05 | 10.10B | 51.48M | -315.00M | -244.00M | -3.5708 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-05-06 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Fortgesetzt | Barclays | Overweight |
| 2026-01-06 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-11-03 | Fortgesetzt | Guggenheim | Buy |
| 2025-10-24 | Bestätigt | B. Riley Securities | Buy |
| 2025-10-21 | Eingeleitet | Mizuho | Outperform |
| 2025-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-07-30 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-03 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2025-06-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-06-02 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-20 | Fortgesetzt | Stifel | Buy |
| 2025-03-13 | Eingeleitet | Citigroup | Buy |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2024-12-02 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-08-26 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2024-04-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-01-04 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Eingeleitet | Truist | Buy |
| 2023-05-05 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-08-15 | Eingeleitet | Jefferies | Buy |
| 2022-08-03 | Eingeleitet | Goldman | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | JP Morgan | Neutral |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2021-09-30 | Eingeleitet | B. Riley Securities | Neutral |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Eingeleitet | Berenberg | Buy |
| 2020-12-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-09-15 | Eingeleitet | BofA Securities | Neutral |
| 2020-09-15 | Eingeleitet | Cowen | Outperform |
| 2020-09-15 | Eingeleitet | Guggenheim | Buy |
| 2020-09-15 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Piper Sandler Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $140 - Moomoo
B of A, Truist raise Kymera Therapeutics price targets - scanx.trade
Eagle Health Investments LP Buys Shares of 166,148 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Merck & Co. Inc. Takes Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
TimesSquare Capital Management LLC Purchases Shares of 157,327 Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Sold by Bank of America Corp DE - MarketBeat
Kymera Therapeutics (KYMR) Advances 3.42% to $121.41 as Protein Degradation Platform Gains Investor AttentionAnalyst Upgrade Stocks - vinanet.vn
Kymera Therapeutics Inc (KYMR) (Q2 2026) Earnings Call Highlight - GuruFocus
Kymera Therapeutics Stock Rockets 17% With 9-Day Winning Streak - Trefis
A 9-Day Winning Streak Has Kymera Therapeutics Stock Up 17% - Trefis
State of Wyoming Purchases New Position in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Kymera Therapeutics (KYMR) Edges Higher by 1.4% as Shares Test Key Resistance at $121.87IV Spike - Vinanet
T. Rowe Price Associates (KYMR) reports 8.6% stake in Kymera Therapeutics - Stock Titan
Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14% - Trefis
A 8-Day Winning Streak Has Kymera Therapeutics Stock Up 14% - Trefis
Atlas Venture funds (KYMR) report 3.4% beneficial stake in Kymera Therapeutics - Stock Titan
Stifel Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Maintains Target Price $132 - Moomoo
Kymera Therapeutics (KYMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Kymera Therapeutics (NASDAQ:KYMR) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
(KYMR) Volatility Zones as Tactical Triggers - Stock Traders Daily
HC Wainwright Issues Negative Outlook for KYMR Earnings - MarketBeat
BofA Securities Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Cuts Target Price to $123 - Moomoo
California State Teachers Retirement System Increases Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
J.P. Morgan Maintains Kymera Therapeutics(KYMR.US) With Buy Rating, Announces Target Price $121 - Moomoo
Why Kymera Therapeutics (NASDAQ:KYMR) Is Drawing Fresh Attention This Week? - Kalkine Media
A Quick Look at Today's Ratings for Kymera Therapeutics(KYMR.US), With a Forecast Between $116 to $139 - Moomoo
Q3 EPS Forecast for Kymera Therapeutics Cut by Analyst - MarketBeat
RBC Capital Downgrades Kymera Therapeutics(KYMR.US) to Hold Rating, Raises Target Price to $112 - moomoo.com
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments - finance.yahoo.com
KYMR Maintains Overweight by Barclays -- Price Target Raised to $139 - GuruFocus
KYMERA THERAPEUTICS, INC. : CITIGROUP RAISES TARGET PRICE TO $135 FROM $120 - Bitget
Kymera Therapeutics (KYMR) Stock Faces A Revenue Durability Reckoning - simplywall.st
Accelerated KT-621 Trial and Narrower Loss Might Change The Case For Investing In Kymera Therapeutics (KYMR) - finance.yahoo.com
KYMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
KYMR Looks 328.3% Overvalued on GF Value™ - GuruFocus
Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kymera Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-08-05 - Seeking Alpha
Kymera Therapeutics, Inc. Stock 12‑Month Price Target Raised to $128.91, Implies 23% Upside - TradingView
Kymera Therapeutics (NASDAQ:KYMR) Releases Earnings Results, Beats Estimates By $0.09 EPS - MarketBeat
Kymera Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kymera Therapeutics Q2 Earnings Call Highlights - MarketBeat
Is Kymera Therapeutics Inc (KYMR) Overvalued After Q2 Earnings B - GuruFocus
Earnings call transcript: Kymera beats Q2 2026 estimates on revenue surge - Investing.com
Kymera Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kymera Therapeutics Q2 Net Loss Narrows, Collaboration Revenue Rises - marketscreener.com
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Earnings Flash (KYMR) Kymera Therapeutics Posts Q2 Loss $0.62 a Share, vs. FactSet Est of $0.71 Loss - marketscreener.com
Earnings Flash (KYMR) Kymera Therapeutics, Inc. Reports Q2 Collaboration Revenue $65.0M, vs. FactSet Est of $32.8M - marketscreener.com
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update - The Manila Times
Finanzdaten der Kymera Therapeutics Inc-Aktie (KYMR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):